ArticleOncotarget2017
Active evolution of memory B-cells specific to viral gH/gL/pUL128/130/131 pentameric complex in healthy subjects with silent human cytomegalovirus infection.
Open access · diamondAbstract read
In one paragraph
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- A Replication-Defective Human Cytomegalovirus Vaccine Elicits Humoral Immune Responses Analogous to Those with Natural Infection.Journal of virology · 2019Trial
- Mapping the monoclonal antibody landscape of human cytomegalovirus.Journal of virology · 2026Review
- Distinct immunologic kinetics and cytomegalovirus reactivation incidence with rituximab- versus obinutuzumab-bendamustine in follicular lymphoma: a single-center case series study.Journal of cancer research and clinical oncology · 2025Observational
- The pentameric complex is not required for congenital CMV transmission in seronegative rhesus macaques.Science translational medicine · 2025Article
- Human cytomegalovirus: pathogenesis, prevention, and treatment.Molecular biomedicine · 2024Review
- Multivalent cytomegalovirus glycoprotein B nucleoside modified mRNA vaccines did not demonstrate a greater antibody breadth.NPJ vaccines · 2024Article
- A single, improbable B cell receptor mutation confers potent neutralization against cytomegalovirus.PLoS pathogens · 2023Article
- Structural basis for HCMV Pentamer recognition by neuropilin 2 and neutralizing antibodies.Science advances · 2022Article
- A conditionally replication-defective cytomegalovirus vaccine elicits potent and diverse functional monoclonal antibodies in a phase I clinical trial.NPJ vaccines · 2021Article
- Potent Bispecific Neutralizing Antibody Targeting Glycoprotein B and the gH/gL/pUL128/130/131 Complex of Human Cytomegalovirus.Antimicrobial agents and chemotherapy · 2021Article
- Monoclonal antibodies targeting nonstructural viral antigens can activate ADCC against human cytomegalovirus.The Journal of clinical investigation · 2021Article
- The N-terminus of varicella-zoster virus glycoprotein B has a functional role in fusion.PLoS pathogens · 2021Article
- Antibody binding to native cytomegalovirus glycoprotein B predicts efficacy of the gB/MF59 vaccine in humans.Science translational medicine · 2020Article
- Article
- Recognition of a highly conserved glycoprotein B epitope by a bivalent antibody neutralizing HCMV at a post-attachment step.PLoS pathogens · 2020Article
- Repertoire characterization and validation of gB-specific human IgGs directly cloned from humanized mice vaccinated with dendritic cells and protected against HCMV.PLoS pathogens · 2020Article
- Past and ongoing adaptation of human cytomegalovirus to its host.PLoS pathogens · 2020Article
- Neutralizing Monoclonal Antibodies Reduce Human Cytomegalovirus Infection and Spread in Developing Placentas.Vaccines · 2019Article
- Identification of adipocyte plasma membrane-associated protein as a novel modulator of human cytomegalovirus infection.PLoS pathogens · 2019Article
- Human cytomegalovirus vaccine development: Immune responses to look into vaccine strategy.Human vaccines & immunotherapeutics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 5 institutions in 2 countries.
Lin XiaTexas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA.
Aimin TangMerck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ, USA.
Weixu MengTexas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA.
Daniel C FreedMerck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ, USA.
Linling HeDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA, USA.
Dai WangMerck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ, USA.
Fengsheng LiMerck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ, USA.
Leike LiTexas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA.
Wei XiongTexas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA.
Xun GuiTexas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA.
Robbie D SchultzTexas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA.
Haotai ChenTexas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA.
Xi HeMerck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ, USA.
Ryan SwoyerMerck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ, USA.
Sha HaMerck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ, USA.
Yaping LiuMerck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ, USA.
Charles D MorrisDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA, USA.
Yu ZhouMerck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ, USA.
I-Ming WangMerck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ, USA.
Qinjian ZhaoState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen, China.
Wenxin LuoState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen, China.
Ningshao XiaState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen, China.
Amy S EspesethMerck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ, USA.
Daria J HazudaMerck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ, USA.
Richard E RuppSealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, TX, USA.
Alan D BarrettSealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, TX, USA.
Ningyan ZhangTexas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA.
Jiang ZhuDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA, USA.
Tong-Ming FuMerck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ, USA.
Zhiqiang AnTexas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA.
Merck & Co., Inc., Rahway, NJ, USA (United States) · USBrown Foundation · USXiamen University · CNScripps Research Institute · USThe University of Texas Medical Branch at Galveston · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human cytomegalovirus (HCMV) can cause life-threatening infection in immunosuppressed patients, and
Indexed as
antiviral antibodyB-cell repertoirehuman antibodieshuman cytomegalovirusneutralization
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.